Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?
β Scribed by Stephen H. Culp; Nizar M. Tannir; E. Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F. Matin; Christopher G. Wood
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 218 KB
- Volume
- 116
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. In a randomized, phase 3 trial, sunitinib demonstrated superior efficacy over interferonβalfa as firstβline therapy in patients with metastatic clearβcell renal cell carcinoma (RCC). On the basis of outcome data from that trial, the authors developed a nomogram for predi
## BACKGROUND. The treatment of patients with metastatic renal cell carcinoma (RCC) continues to pose a major clinical challenge. Previous studies have suggested that infusional floxuridine (FUDR) has antitumor efficacy and is well tolerated. To the authors knowledge the combination of infusional F
## Abstract ## BACKGROUND. The role of nephronβsparing surgery (NSS) showed promise in patients with metastatic renal cell carcinoma (MRCC). The diseaseβspecific survival of patients with MRCC was compared according to the type of surgery, NSS (N = 45) versus radical nephrectomy (RN) (N = 732), in